Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab consolidation after dCCRT in LA-ESCC
NCT04212598Phase 2Completed
- Sponsor
- Wuhan University
- Start
- Aug 2020
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Wuhan University. Started Aug 2020; status: completed.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04212598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04212598.